Biotech Values

[DewDiligence]

PRDS—…it's a hedge, but also a means of forcing myself to better track ENTA competition.

There are a few other companies who are trying to improve on PFE’s Paxlovid. For ENTA longs, buying PRDS as a hedge seems reasonable, but I’m disinclined to pay more than the $10 the institutional shareholders paid in the recent $75M raise, so I’m staying on the sidelines for now.